Lung Cancer News and Research

Latest Lung Cancer News and Research

Duke University Medical Center, LabCorp form joint venture to commercialize new biomarkers

Duke University Medical Center and Laboratory Corporation of America Holdings announced today the formation of a joint venture to commercialize new biomarkers. The new entity is designed to speed the translation of newly discovered biomarkers into widely available clinical tools that can measure individual therapeutic responses, predict disease progression, and evaluate any number of biologic or disease-causing processes.

21 Apr 2010

Gemin X Pharmaceuticals closes $16 million Series D financing

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.

21 Apr 2010

Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.

20 Apr 2010

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

NewLink Genetics Corporation announced today data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer treated with its HyperAcute®-Lung cancer immunotherapy experienced favorable median survival. The data were presented at the 101st American Association for Cancer Research (AACR) Annual Meeting.

20 Apr 2010

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical trials.

20 Apr 2010

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.

20 Apr 2010

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

BioMarin Pharmaceutical Inc. announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.

19 Apr 2010

Sentry Air Systems announces equipment compliance with OSHA's hexavalent chromium regulation

The Occupational Health and Safety Administration (OSHA) is enforcing strict regulations regarding worker exposure to hexavalent chromium in several industries. Hexavalent chromium, a volatized and oxidized form of chromium, has been identified as a carcinogen. OSHA has subsequently established stringent regulations for workers who are potentially exposed to it in the general, construction, shipyard, and marine terminal industries.

19 Apr 2010

Results of BATTLE Trial presented at AACR 2010

Lung cancer is the number one cause of cancer death in men and women, but huge randomized trials of thousands of patients have either failed completely or shown negligible survival differences.

19 Apr 2010

CCS organizes Women's Brunch on breast cancer screening

The Canadian Cancer Society (CCS) is organizing a Women's Brunch for the media, to remind women of the importance of screening as a way to fight breast cancer.

17 Apr 2010

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

17 Apr 2010

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

Victims of sudden cardiac arrest who are treated with automated external defibrillators by bystanders have a much greater chance of survival than their counterparts, according to landmark research by the Resuscitation Outcomes Consortium, just published in the Journal of the American College of Cardiology.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Illinois' tobacco tax would bring in $297.6M in new revenue, reduce youth smoking

A new poll released today finds that 74 percent of Illinois voters support raising the tobacco tax by $1 per pack to cut the state's budget deficit and reduce youth tobacco use.

16 Apr 2010

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

The University Hospital of Zurich has become the first medical center in the world to commence treating cancer patients with the revolutionary TrueBeam system from Varian Medical Systems, a new platform for image-guided radiotherapy and radiosurgery that was designed from the ground up to treat a moving target with unprecedented speed and precision.

16 Apr 2010

IBA's PBS system for Proton Therapy granted CE Mark

IBA's second generation Pencil Beam Scanning system for Proton Therapy, which further enhances the performance of anti-cancer proton treatments, has been granted the CE Mark, certifying that the product has met European Union medical device regulations.

16 Apr 2010

Boston Scientific receives FDA clearance to resume distribution of COGNIS CRT-Ds and TELIGEN ICDs

Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.

16 Apr 2010

Current screening methods for FOBT are often not appropriate

More than 75 percent of primary care physicians in the United States who order or perform the fecal occult blood test as a screening option for colorectal cancer perform an in-office test rather than relying on the home-based test, even though the home-based test is more accurate, a study by the Centers for Disease Control and Prevention has found.

16 Apr 2010

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Duke University Medical Center, LabCorp form joint venture to commercialize new biomarkers

Gemin X Pharmaceuticals closes $16 million Series D financing

Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

Sentry Air Systems announces equipment compliance with OSHA's hexavalent chromium regulation

Results of BATTLE Trial presented at AACR 2010

CCS organizes Women's Brunch on breast cancer screening

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Illinois' tobacco tax would bring in $297.6M in new revenue, reduce youth smoking

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

IBA's PBS system for Proton Therapy granted CE Mark

Boston Scientific receives FDA clearance to resume distribution of COGNIS CRT-Ds and TELIGEN ICDs

Current screening methods for FOBT are often not appropriate

Decoding genomes from 25,000 cancer samples

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

The ultimate guide to lung research tools and protocols eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in